Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Takes Advisory Committee Off Life Support, Adds Analgesics To Title

This article was originally published in The Pink Sheet Daily

Executive Summary

The Anesthetics and Life Support Drugs Advisory Committee discussed analgesics at 11 of 14 meetings during the past four years, anesthetics at three, and life support drugs at none.

You may also be interested in...

Opioid REMS Needs Legislation Mandating Physician Training For Full Implementation

Training would be required for DEA licensing as FDA goes with advisory committee opinion that it should not be voluntary.

Pediatric Researcher Expresses Frustration With FDA Delay On Ketamine Trial

K.J.S. "Sunny" Anand, director of critical care at Le Bonheur Children's Hospital, said he has been waiting two and a half years for the agency to clear an IND for the drug.

Opioid Abuse-Deterrence Labeling May Be A Long Way Off After Panel Rejects Validity Of Broad Claim

Labeling should be specific, such as a claim for injection-resistance, committee members tell FDA.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts